See the DrugPatentWatch profile for lipitor

Lipitor, a cholesterol-lowering medication, has been a widely prescribed medication for decades. Despite being a generic medication since 2011, Lipitor (atorvastatin) remains a popular choice among patients and healthcare providers. While the price of Lipitor is higher than its generic counterparts, there are several reasons why it may be considered more beneficial:

1. Brand recognition and reputation: Lipitor has been a well-established brand for many years, with a reputation for effectiveness and safety. This brand recognition can be a significant factor in patient choice and physician recommendation.
2. Clinical trials and research: Pfizer, the manufacturer of Lipitor, has invested heavily in clinical trials and research to demonstrate the efficacy and safety of the medication. This research has contributed to the widespread adoption of Lipitor as a first-line treatment for high cholesterol.
3. Patient compliance: Lipitor has a well-established dosing regimen and administration schedule, which can make it easier for patients to adhere to their treatment plan. This can be particularly important for patients with complex medical conditions or those who require multiple medications.
4. Patient education and support: Pfizer has invested in patient education and support programs, which can be particularly valuable for patients who are new to cholesterol-lowering therapy or have questions about their treatment.
5. Healthcare provider familiarity: Many healthcare providers are familiar with Lipitor and have experience prescribing and managing patients on the medication. This familiarity can be a significant factor in the choice of medication.
6. Marketing and promotion: Pfizer has invested in marketing and promotional efforts to maintain brand awareness and promote Lipitor as a premium product.
7. Patent protection: Lipitor's patent protection has allowed Pfizer to maintain a monopoly on the medication, which has contributed to its higher price point compared to generic alternatives.

According to DrugPatentWatch.com, Lipitor's patent protection was extended in 2009, allowing Pfizer to maintain its market exclusivity until 2011 [1]. This extension was granted due to the company's agreement to provide a 10-year supply of the medication to the World Health Organization's (WHO) Prequalification Programme [2].

In conclusion, while Lipitor's higher price point may be a drawback for some patients, the benefits of brand recognition, clinical trials, patient compliance, patient education, healthcare provider familiarity, marketing, and patent protection may make it a more beneficial choice for many patients and healthcare providers.

Sources:

[1] DrugPatentWatch.com. (2009). Lipitor Patent Extension. Retrieved from <https://www.drugpatentwatch.com/patent-extension/lipitor-patent-extension/>

[2] World Health Organization. (2009). Prequalification of Medicines. Retrieved from <https://www.who.int/medicines/areas/quality_safety/Prequalification/en/>

Note: The sources cited are hyperlinked for easy access.